An announcement from Septerna, Inc. ( (SEPN) ) is now available.
Septerna, Inc. announced its participation in the TD Cowen 45th Annual Health Care Conference in March 2025, highlighting its strategic focus on advancing its oral small molecule GPCR-targeted programs. The company disclosed the discontinuation of its SEP-786 development due to unexpected adverse events and plans to pivot towards a next-generation oral PTH1R agonist, emphasizing its commitment to addressing unmet medical needs in hypoparathyroidism and other conditions.
More about Septerna, Inc.
Septerna, Inc. operates in the pharmaceutical industry, focusing on pioneering new GPCR (G protein-coupled receptor) drug discovery using oral small molecules. The company leverages its proprietary Native Complex Platform™ to develop therapies for diseases such as hypoparathyroidism, Graves’ disease, and metabolic disorders, aiming to unlock difficult-to-drug GPCRs and expand market opportunities.
YTD Price Performance: -69.70%
Average Trading Volume: 552,566
Current Market Cap: $287.3M
For a thorough assessment of SEPN stock, go to TipRanks’ Stock Analysis page.